Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Fridays with Adam Feuerstein #1


Who's the expert?

Name: Adam Feuerstein

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. A veteran journalist, Adam was most recently Senior Columnist at TheStreet, where he wrote about biotech and drug stocks. Adam lives near Boston with his wife, two kids and Bo, an insanely cute boxer/mutt.

Interview Questions

Join now and add your questions for Adam F.! 

Added By: joe_mccann

what are your thoughts about GBT & DBVT?

Added By: aklapholz

Can you gauge the impact on VRTX Cf franchise if GLPG competing product was shown to be efficacious?

Added By: alexander poulos

Always a bad sign when a drug gets returned from a partner but what do you think about ARDX data? Met end-points.  Then there is the IBS-C indication coming then later hyperkalemia drug(s).

Added By: bin2gray

Do you think there's any more appetite in the market for more kinase inhibitor focused companies?  Thoughts on BPMC? LOXO? Ignyta?

Added By: userd16bd1d0

Do you think there's still a future for CAR-T companies?  KITE, JUNO, UNUM?

Added By: userd16bd1d0

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.